Ground Swell Capital LLC Takes Position in United Therapeutics Corporation $UTHR

Ground Swell Capital LLC purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the 3rd quarter, HoldingsChannel.com reports. The fund purchased 1,191 shares of the biotechnology company’s stock, valued at approximately $499,000. United Therapeutics comprises approximately 1.1% of Ground Swell Capital LLC’s portfolio, making the stock its 28th biggest holding.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. CWM LLC increased its stake in United Therapeutics by 204.3% during the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock worth $1,492,000 after buying an additional 3,487 shares in the last quarter. AXQ Capital LP lifted its position in shares of United Therapeutics by 495.4% in the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after acquiring an additional 3,235 shares in the last quarter. AE Wealth Management LLC boosted its stake in shares of United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 3,424 shares during the last quarter. Great Lakes Advisors LLC increased its position in shares of United Therapeutics by 194.7% during the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after purchasing an additional 2,975 shares in the last quarter. Finally, Optimize Financial Inc acquired a new position in United Therapeutics in the 3rd quarter valued at $444,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

Shares of UTHR opened at $476.13 on Friday. The firm has a 50-day simple moving average of $486.33 and a two-hundred day simple moving average of $431.32. The stock has a market cap of $20.50 billion, a PE ratio of 18.04, a P/E/G ratio of 2.53 and a beta of 0.85. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99.

Analysts Set New Price Targets

A number of research analysts have weighed in on UTHR shares. Royal Bank Of Canada raised their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. HC Wainwright increased their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. UBS Group boosted their price target on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. Finally, Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a report on Wednesday, October 29th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $509.50.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $474.65, for a total value of $10,679,625.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $483.25, for a total value of $4,010,975.00. Following the transaction, the executive vice president owned 36,781 shares in the company, valued at $17,774,418.25. This trade represents a 18.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 502,214 shares of company stock worth $242,241,993. Insiders own 10.30% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.